ARWR vs. ELA
ARWR (Arrowhead Pharmaceuticals, Inc.) and ELA (Envela Corporation) are both stocks. ARWR operates in Biotechnology (Healthcare), while ELA operates in Luxury Goods (Consumer Cyclical). Over the past 10 years, ARWR returned 31.09%/yr vs 44.37%/yr for ELA. At a 0.06 correlation, their price movements are largely independent.
Performance
ARWR vs. ELA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ARWR achieves a 23.51% return, which is significantly lower than ELA's 105.75% return. Over the past 10 years, ARWR has underperformed ELA with an annualized return of 31.09%, while ELA has yielded a comparatively higher 44.37% annualized return.
ARWR
- 1D
- 0.22%
- 1M
- 9.41%
- YTD
- 23.51%
- 6M
- 18.84%
- 1Y
- 435.25%
- 3Y*
- 32.51%
- 5Y*
- -1.42%
- 10Y*
- 31.09%
ELA
- 1D
- 0.18%
- 1M
- 15.43%
- YTD
- 105.75%
- 6M
- 108.09%
- 1Y
- 365.82%
- 3Y*
- 58.00%
- 5Y*
- 40.89%
- 10Y*
- 44.37%
ARWR vs. ELA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ARWR Arrowhead Pharmaceuticals, Inc. | 23.51% | 253.14% | -38.56% | -24.56% | -38.82% | -13.59% | 20.97% | 410.71% | 237.50% | 137.42% |
ELA Envela Corporation | 105.75% | 86.35% | 47.74% | -7.60% | 29.24% | -21.73% | 285.19% | 193.54% | -50.55% | -25.00% |
Correlation
The correlation between ARWR and ELA is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.11 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.18 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.19 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.12 |
Correlation (All Time) Calculated using the full available price history since Jan 6, 1997 | 0.06 |
The correlation between ARWR and ELA shifts across timeframes, from 0.06 (all time) to 0.19 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
ARWR:
$11.68B
ELA:
$714.77M
ARWR:
-$2.16
ELA:
$0.81
ARWR:
18.39
ELA:
2.46
ARWR:
19.50
ELA:
9.42
ARWR:
$622.01M
ELA:
$291.15M
ARWR:
$529.27M
ELA:
$62.58M
ARWR:
-$168.38M
ELA:
$22.99M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ARWR vs. ELA — Risk / Return Rank
ARWR
ELA
ARWR vs. ELA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Arrowhead Pharmaceuticals, Inc. (ARWR) and Envela Corporation (ELA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ARWR | ELA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.54 | ||
| Sortino ratioReturn per unit of downside risk | +0.44 | ||
| Omega ratioGain probability vs. loss probability | 1.68 | 1.62 | +0.06 |
| Calmar ratioReturn relative to maximum drawdown | 17.81 | 16.94 | +0.87 |
| Martin ratioReturn relative to average drawdown | 49.05 | 52.14 | -3.08 |
Loading charts...
Drawdowns
ARWR vs. ELA - Drawdown Comparison
The maximum ARWR drawdown since its inception was -99.24%, roughly equal to the maximum ELA drawdown of -97.32%. Use the drawdown chart below to compare losses from any high point for ARWR and ELA.
Loading charts...
Drawdown Indicators
| ARWR | ELA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.24% | -97.32% | -1.92% |
Max Drawdown (1Y)Largest decline over 1 year | -24.64% | -21.77% | -2.87% |
Max Drawdown (3Y)Largest decline over 3 years | -74.70% | -59.24% | -15.46% |
Max Drawdown (5Y)Largest decline over 5 years | -88.94% | -61.53% | -27.41% |
Max Drawdown (10Y)Largest decline over 10 years | -88.96% | -78.03% | -10.93% |
Current DrawdownCurrent decline from peak | -49.54% | 0.00% | -49.54% |
Average DrawdownAverage peak-to-trough decline | -81.19% | -57.58% | -23.61% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.93% | 7.06% | +1.87% |
Volatility
ARWR vs. ELA - Volatility Comparison
The current volatility for Arrowhead Pharmaceuticals, Inc. (ARWR) is 14.13%, while Envela Corporation (ELA) has a volatility of 18.34%. This indicates that ARWR experiences smaller price fluctuations and is considered to be less risky than ELA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ARWR | ELA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.13% | 18.34% | -4.21% |
Volatility (6M)Calculated over the trailing 6-month period | 36.34% | 58.82% | -22.48% |
Volatility (1Y)Calculated over the trailing 1-year period | 65.46% | 71.30% | -5.84% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 65.02% | 54.25% | +10.77% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 74.19% | 65.64% | +8.55% |
Dividends
ARWR vs. ELA - Dividend Comparison
Neither ARWR nor ELA has paid dividends to shareholders.
Financials
ARWR vs. ELA - Financials Comparison
This section allows you to compare key financial metrics between Arrowhead Pharmaceuticals, Inc. and Envela Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ARWR and ELA have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ELA has higher volatility (18.34%) compared to ARWR (14.13%). In terms of maximum drawdown, ARWR dropped -99.24% vs ELA's -97.32%.
ARWR currently has the higher Sharpe Ratio (6.72 vs 5.18), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ARWR and ELA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer